These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 12951755)

  • 21. The impact of standard high-flux polysulfone versus novel high-flux polysulfone dialysis membranes on inflammatory markers: a randomized, single-blinded, controlled clinical trial.
    Kerr PG; Sutherland WH; de Jong S; Vaithalingham I; Williams SM; Walker RJ
    Am J Kidney Dis; 2007 Apr; 49(4):533-9. PubMed ID: 17386321
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of gentamicin pharmacokinetics in patients hemodialyzed with high-flux polysulfone membranes.
    Amin NB; Padhi ID; Touchette MA; Patel RV; Dunfee TP; Anandan JV
    Am J Kidney Dis; 1999 Aug; 34(2):222-7. PubMed ID: 10430966
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influence of cellulose triacetate hemodialyzers on vancomycin pharmacokinetics.
    Welage LS; Mason NA; Hoffman EJ; Odeh RM; Dombrouski J; Patel JA; Swartz RD
    J Am Soc Nephrol; 1995 Oct; 6(4):1284-90. PubMed ID: 8589298
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Streptogramins and glycopeptides].
    Tsuji A
    Nihon Rinsho; 2007 Feb; 65 Suppl 2 Pt. 1():360-6. PubMed ID: 17455646
    [No Abstract]   [Full Text] [Related]  

  • 25. Health economics assessment study of teicoplanin versus vancomycin in Gram-positive infections.
    Portolés A; Palau E; Puerro M; Vargas E; Picazo JJ
    Rev Esp Quimioter; 2006 Mar; 19(1):65-75. PubMed ID: 16688294
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preferable timing of therapeutic drug monitoring in patients with impaired renal function treated with once-daily administration of vancomycin.
    Takahashi Y; Takesue Y; Takubo S; Ishihara M; Nakajima K; Tsuchida T; Ikeuchi H; Uchino M
    J Infect Chemother; 2013 Aug; 19(4):709-16. PubMed ID: 23345049
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of bactericidal activities of intermittent and continuous infusion dosing of vancomycin against methicillin-resistant Staphylococcus aureus and Enterococcus faecalis.
    Klepser ME; Patel KB; Nicolau DP; Quintiliani R; Nightingale CH
    Pharmacotherapy; 1998; 18(5):1069-74. PubMed ID: 9758317
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Approaching and analyzing a large literature on vancomycin monitoring and pharmacokinetics.
    Lee P; DiPersio D; Jerome RN; Wheeler AP
    J Med Libr Assoc; 2007 Oct; 95(4):374-80. PubMed ID: 17971884
    [No Abstract]   [Full Text] [Related]  

  • 29. Comparison of the effects of three haemodialysis membranes on vancomycin disposition.
    Alwakeel J; Najjar TA; al-Yamani MJ; Huraib S; al-Haider A; Abu-aisha H
    Int Urol Nephrol; 1994; 26(2):223-8. PubMed ID: 8034435
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Leukocyte, platelet and endothelial activation in patients with acute renal failure treated by intermittent hemodialysis.
    de Sá HM; Freitas LA; Alves VC; Garção MF; Rosa MA; Marques AA
    Am J Nephrol; 2001; 21(4):264-73. PubMed ID: 11509797
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of vancomycin and gentamicin dialysis clearance using in vivo and in vitro systems.
    Pinner NA; Canada RB; Broyles JE; Hudson JQ
    Ren Fail; 2012; 34(6):703-7. PubMed ID: 22463708
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A protocol for developing a clinical practice guideline for therapeutic drug monitoring of vancomycin.
    Ye ZK; Chen K; Chen YL; Zhai SD
    J Huazhong Univ Sci Technolog Med Sci; 2016 Jun; 36(3):469-472. PubMed ID: 27376822
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Normal T lymphocyte function in patients with end-stage renal disease hemodialyzed with 'high-flux' polysulfone membranes.
    Degiannis D; Czarnecki M; Donati D; Homer L; Eisinger RP; Raska K; Raskova J
    Am J Nephrol; 1990; 10(4):276-82. PubMed ID: 2240054
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fresenius Polysulfone--membrane developments to meet clinical demands.
    Clin Nephrol; 1994 Jul; 42 Suppl 1():S1-60. PubMed ID: 7923976
    [No Abstract]   [Full Text] [Related]  

  • 35. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists.
    Rybak M; Lomaestro B; Rotschafer JC; Moellering R; Craig W; Billeter M; Dalovisio JR; Levine DP
    Am J Health Syst Pharm; 2009 Jan; 66(1):82-98. PubMed ID: 19106348
    [No Abstract]   [Full Text] [Related]  

  • 36. An update on vancomycin dosing and monitoring practices in hemodialysis patients.
    Zhang M; Dresser L; Battistella M
    CANNT J; 2013; 23(4):25-7; quiz 28-9. PubMed ID: 24660521
    [No Abstract]   [Full Text] [Related]  

  • 37. Urea kinetics and dialysis treatment time predict vancomycin elimination during high-flux hemodialysis.
    Schaedeli F; Uehlinger DE
    Clin Pharmacol Ther; 1998 Jan; 63(1):26-38. PubMed ID: 9465839
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New hemodialysis membranes and vancomycin clearance.
    Meyer CC; Calis KA
    Am J Health Syst Pharm; 1995 Dec; 52(24):2794-6. PubMed ID: 8748565
    [No Abstract]   [Full Text] [Related]  

  • 39. Hemodiafiltration for vancomycin overdose in a patient with end-stage renal failure.
    Akil IO; Mir S
    Pediatr Nephrol; 2001 Dec; 16(12):1019-21. PubMed ID: 11793092
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is re-dosing of vancomycin necessary?
    Khan JH; Davis EA
    Ann Thorac Surg; 2006 Feb; 81(2):789. PubMed ID: 16427916
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.